United Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade United Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About UTHR

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. 

CEO
Martine A. Rothblatt
CEOMartine A. Rothblatt
Employees
1,400
Employees1,400
Headquarters
Silver Spring, Maryland
HeadquartersSilver Spring, Maryland
Founded
1996
Founded1996
Employees
1,400
Employees1,400

UTHR Key Statistics

Market cap
22.92B
Market cap22.92B
Price-Earnings ratio
18.76
Price-Earnings ratio18.76
Dividend yield
Dividend yield
Average volume
521.20K
Average volume521.20K
High today
$535.33
High today$535.33
Low today
$520.97
Low today$520.97
Open price
$534.11
Open price$534.11
Volume
332.98K
Volume332.98K
52 Week high
$549.50
52 Week high$549.50
52 Week low
$266.98
52 Week low$266.98

Stock Snapshot

The current United Therapeutics(UTHR) stock price is $523.09, with a market capitalization of 22.92B. The stock trades at a price-to-earnings (P/E) ratio of 18.76.

As of 2026-03-29, United Therapeutics(UTHR) stock has fluctuated between $520.97 and $535.33. The current price stands at $523.09, placing the stock +0.4% above today's low and -2.3% off the high.

United Therapeutics(UTHR) shares are trading with a volume of 332.98K, against a daily average of 521.2K.

In the last year, United Therapeutics(UTHR) shares hit a 52-week high of $549.50 and a 52-week low of $266.98.

In the last year, United Therapeutics(UTHR) shares hit a 52-week high of $549.50 and a 52-week low of $266.98.

UTHR News

Investing.com 3d
Rothblatt, United Therapeutics CEO, sells $5.1m in UTHR stock - Investing.com

...

Rothblatt, United Therapeutics CEO, sells $5.1m in UTHR stock - Investing.com
Simply Wall St 5d
Assessing United Therapeutics Valuation As Organ Programs Shape Its 2026 Narrative

Advertisement Why United Therapeutics Is On Investors’ Radar United Therapeutics (UTHR) is drawing attention after a recent move in its share price, with the...

Assessing United Therapeutics Valuation As Organ Programs Shape Its 2026 Narrative

Analyst ratings

75%

of 16 ratings
Buy
75%
Hold
25%
Sell
0%

People also own

Based on the portfolios of people who own UTHR. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.